Glufosfamide (b-D-glucosyl-ifosfamide mustard) is a new agent for cancer chemotherapy. Its pharmacology is similar to commonly used oxazaphosphorines, but it does not require activation by hepatic cytochrome P-450 and preclinically demonstrates lower nephrotoxicity and myelosuppression than ifosfamide. The aim of the study was a comparison of the drug resistance profiles of glufosfamide and other oxazaphosphorines in childhood acute leukemias. Leukemic cells, taken from children with ALL on diagnosis (n = 41), ALL on relapse (n = 12) and AML on diagnosis (n Vol. 49 No.
= 13) were analyzed by means of the MTT assay. The following drugs were tested: glufosfamide (GLU), 4-HOO-ifosfamide (IFO), 4-HOO-cyclophosphamide (CYC) and mafosfamide cyclohexylamine salt (MAF). In the group of initial ALL samples median cytotoxicity values for GLU, IFO, CYC and MAF were 15.5, 33.8, 15.7 and 7.8 mM, respectively. In comparison with initial ALL samples, the relative resistance for GLU and IFO in relapsed ALL samples was 1.9 (p = 0.049) and 1.3 (ns), and in initial AML samples 31 (p < 0.001) and 5 (p = 0.001), respectively. All oxazaphosphorines presented highly significant cross-resistance. Glufosfamide presented high activity against lymphoblasts both on diagnosis and on relapse.
Oxazaphosphorines are a class of alkylating agents with a high experimental and clinical antitumor activity. Cyclophosphamide and ifosfamide are prodrugs, which need metabolic activation by cytochrome P-450 enzymes of the liver to generate the cytotoxic species [1] . The goal of search for analogues has been to synthesize "activated" oxazaphosphorines, which hydrolyze spontaneously to form primary 4-hydroxy-metabolites. However, one of those agents, mafosfamide, was difficult to develop clinically because of severe pain at the injection site, which probably resulted from acrolein generated during spontaneous degradation of the molecule during infusion [2, 3] . Glufosfamide (b-D-glucosyl-isophosphoramide mustard) is a new agent for cancer chemotherapy with pharmacology similar to commonly used oxazaphosphorines, which does not require activation by cytochrome P-450 [4, 5] . Glufosfamide preclinically demonstrated less nephrotoxicity and myelosuppression than ifosfamide [6] . The cytotoxic activity of glufosfamide is dependent on DNA alkylating properties [4] . A more detailed analysis of the mechanism of glufosfamide action showed that the drug impaired protein and DNA synthesis, and triggered the activation of poly(ADP-ribose) polymerase (PARP), an enzyme specifically sensing DNA strand-breaks [7] . As cyclophosphamide and ifosfamide are widely used in the therapy of acute lymphoblastic leukemia (ALL), both initial (iALL) and at relapse (rALL), the objective of the study was an analysis of the drug resistance profile of glufosfamide in comparison with other oxazaphosphorines in childhood acute leukemia.
MATERIALS AND METHODS
Leukemic cells were taken from 24 girls and 42 boys, aged 0.4-18 yrs (median 7.0 yrs) with diagnoses: initial ALL (iALL, n = 41), ALL on relapse (rALL, n = 12) and initial acute myeloblastic leukemia (iAML, n = 13). Drug resistance was analyzed by means of the 4-days MTT assay [8] . Only samples with at least 80% leukemic cells in the isolate suspension were analyzed. The following drugs belonging to the group of oxazaphosphorines were tested: glufosfamide (GLU), 4-HOO-ifosfamide (IFO), 4-HOO-cyclophosphamide (CYC) and mafosfamide cyclohexylamine salt (MAF) (all provided kindly by ASTA Medica, Frankfurt, Germany) ( Fig. 1 , Table 1 ). Drug concentration lethal to 50% of tested cells (LC 50 ) was used as a measure of cytotoxicity. Differences between groups were compared with Mann-Whitney U test. Correlation between cytotoxicity of drugs was determined by Spearman's rho coefficient. The study was approved by the Local Ethics Committee of Medical University (Bydgoszcz, Poland).
RESULTS AND DISCUSSION
In the group of initial ALL samples, equivalent LC 50 values for GLU, IFO, CYC and MAF were 15.5, 33.8, 15.7 and 7.8 mM, respectively. The relative resistance in relapsed ALL samples, in comparison with initial ALL samples, was 1.9 (p = 0.049) for GLU and 1.3 (p > 0.05) for IFO. The group of initial AML samples was 31-fold more resistant (p < 0.001) to GLU and 5-fold (p = 0.001) to IFO than iALL samples (Table 2 ). All oxazaphosphorines showed highly significant cross-resistance within each pair of drugs (Table 3) .
Glufosfamide shows similarity to ifosfamide in its cytotoxic effects, due to the formation of ifosfamide mustard, a metabolite of both compounds [7] . [4] . Another important difference between these drugs is that it was possible to provoke resistance of SKOV 3 cells to continuous treatment with ifosfamide but not to glufosfamide [7] . We tested if glufosfamide might be able to circumvent resistance to cyclophosphamide and ifosfamide in samples of childhood acute leukemias. Glufosfamide presented a favourable cytotoxicity profile in ALL cells both on diagnosis and at relapse. However, cross-resistance with other oxazaphosphorines and other tested drugs was observed. Should the toxicity profile be taken into account, this drug might be considered useful in future clinical practice. Since cyclophosphamide is often used in the conditioning regimen before allogenic or autologous hemopoietic stem cell transplantation, and mafosfamide is used for Vol. 49 Oxazaphosphorines in vitro activity 223 bone marrow purging [9] , it seems that with its cytotoxicity profile glufosfamide might be also used in transplantation procedures in acute lymphoblastic leukemia. On the other hand, very weak activity of glufosfamide was observed against AML cells, typical also for other drugs belonging to this group. Concluding, the in vitro activity of glufosfamide is comparable to other oxazaphosphorines. Glufosfamide shows high activity against lymphoblasts both on diagnosis and on relapse, but because of high cross-resistance it cannot circumvent resistance to other oxazaphosphorines.
Authors thank Beata Ko³odziej for technical assistance. 
